Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients

  • 72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p = 0.0006)
  • Company preparing to complete submissions for early market access in the U.S., U.K., Europe and Australia
  • WHO recently accepted the proprietary brand name Herlystic™ for OST-HER2 (daznelimgene lisbac).

Grasonville, Maryland--(Newsfile Corp. - October 6, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced statistically significant final 3-year overall survival benefit for OST-HER2-treated patients in its Phase 2b trial in pulmonary metastatic osteosarcoma, when compared with a combined published historical control. The analysis is from the Company's Phase 2b trial for the prevention or delay of recurrence in patients with fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program"). The final 3-year overall survival rate among OST-HER2 treated patients was 72.7 percent, compared with 45.8 percent of patients in the comparable combined historical control group (p = 0.0006, 41 total enrolled patients, and four patients lost to follow-up).